Ovarian cancer is the sixth most common cancer in women in the United States and Europe ([@bib12]). Most patients present with advanced stage disease and though the majority of them experience remission after surgery and a frontline platinum/taxane-based regimen, the relapse rate is 80% ([@bib1]). Historically, the efficacy of chemotherapy retreatment in relapsed ovarian cancer has been correlated with prior platinum sensitivity, namely with the platinum-free interval (PFI; [@bib3]). Although a PFI greater than 6 months predicts platinum sensitivity, within this group, patients with an interval greater than 12 months are considered fully sensitive and commonly retreated with platinum-containing regimens, whereas patients with a PFI between 6 and 12 months are believed to have partially platinum-sensitive relapse. In this patient subset, both preclinical and clinical data suggest that the artificial prolongation of PFI with a nonplatinum-based therapy may be beneficial in reversing platinum resistance ([@bib15]; [@bib18]). Conversely, patients who progress while receiving firstline therapy or within 6 months from its completion are considered to have refractory/resistant relapse, which is typically retreated with a monotherapy of nonplatinum agents, such as pegylated liposomal doxorubicin (PLD), gemcitabine, or topotecan, with a disappointing median survival of about 10 months from the time of recurrence ([@bib20]). In view of the dismal prognosis, new treatment options are therefore required to improve outcome in recurrent ovarian cancer, especially in platinum-refractory/resistant relapse.

Tumour necrosis factor (TNF) has shown a powerful preclinical activity that is primarily mediated by inducing apoptosis of cancer endothelial cells ([@bib4]) and promoting antitumour immune responses ([@bib25]). However, the early-stage clinical trials were hampered by severe toxicities when TNF was given systemically, whereas the locoregional delivery by isolated perfusion of high-dose TNF plus chemotherapy has been associated with increased response rates in melanoma, sarcoma, and liver cancer ([@bib14]).

To exploit a ligand-directed approach, the NGR-hTNF (asparagine--glycine--arginine--human TNF) was prepared by fusing the N terminus of TNF with the C terminus of the peptide NGR, which is able to selectively recognise a CD13 isoform overexpressed on tumour endothelium ([@bib5]). Remarkably, CD13 is not (or barely) expressed in normal blood vessels, and its crucial role into the pathological development of new vessels from pre-existing vessels (i.e., angiogenesis) has been recently confirmed in a CD13-null model ([@bib19]). In preclinical models, NGR-hTNF induced antitumour effects 10-fold higher than the untargeted TNF and displayed a biphasic dose--response curve, with activity shown even at very low doses. Interestingly, tumour regressions induced by low doses of NGR-hTNF were accompanied by protective immunity, implying that the targeted delivery of TNF to tumour may also improve its immunotherapeutic properties ([@bib5]).

Besides the ability of inducing apoptosis of tumour endothelial cells, NGR-hTNF also decreases the interstitial fluid pressure by altering the integrity of endothelial cell barrier, a process pivotal in facilitating the intratumoural chemotherapy uptake. The mechanism by which NGR-hTNF increases endothelial permeability and drug penetration in tumour relies on rapid disassembly of vascular endothelial-cadherin-dependent adherence junctions and formation of intercellular gaps that are followed by vascular damage at later time points ([@bib7]). Consistently with a selective activity, even low doses of NGR-hTNF exerted synergistic effects *in vivo* when combined with various chemotherapeutic drugs, especially doxorubicin, without increasing the *in vitro* cytotoxicity of chemotherapy, likely because of indirect effects on host cells rather than direct effects on tumour cells ([@bib6]). Indeed, synergism was sequence- and time-dependent, being observed when NGR-hTNF was given 2 h before chemotherapy dosing, and not with shorter or longer time intervals ([@bib22]). Notably, the synergism with doxorubicin has been shown in immunocompetent mice, but not in athymic nude mice lacking functionally mature T lymphocytes ([@bib23]).

The rationale for testing an antivascular approach in ovarian cancer is highly appealing. Both preclinical and clinical data have confirmed the key role of angiogenesis in ovarian cancer pathophysiology ([@bib13]). Moreover, CD13 is highly expressed in ovarian cancer, and CD13-overexpressing tumours resistant to cisplatin *in vivo* do not show reduced sensitivity *in vitro*, thus suggesting that inadequate drug delivery to tumour rather than CD13-induced resistance is involved ([@bib28]). Interestingly, the highest doxorubicin sensitivity *in vivo* is observed in tumour microenvironments with increased vascular permeability ([@bib17]).

Two single-agent phase I trials established the maximum tolerated dose of NGR-hTNF at 45 *μ*g m^−2^ ([@bib29]) and the optimal biological dose at 0.8 *μ*g m^−2^ ([@bib10]), with both doses delivered every 3 weeks. Given the equivalent activity and better tolerability, the low dose was used for further clinical testing. Two single-agent phase II trials documented the clinical activity of NGR-hTNF 0.8 *μ*g m^−2^ in liver cancer ([@bib24]) and mesothelioma ([@bib11]) patients who were refractory/resistant to standard treatments. A phase I combination trial selected NGR-hTNF 0.8 *μ*g m^−2^ plus standard doxorubicin doses (60 or 75 mg m^−2^) for phase II testing, with a promising disease control experienced by 73% of patients for a median time of 5.5 months, without apparent increase of doxorubicin-related toxicity ([@bib9]).

The present phase II trial was undertaken to evaluate activity and safety of the combination of NGR-hTNF and doxorubicin in advanced ovarian cancer patients relapsing after platinum/taxane-based chemotherapy. Doxorubicin was used in this trial because of lack of preclinical and phase I clinical data with PLD.

Methods
=======

Patient eligibility
-------------------

Patients older than age 18 years, with advanced ovarian cancer previously treated with at least one platinum-based regimen (either cisplatin or carboplatin plus paclitaxel) and with radiologic evidence of tumour progression on treatment or within 6 months of completing therapy (platinum-refractory/resistant relapse), or between 6 to 12 months (partially platinum-sensitive relapse), were eligible. Patients were also required to have at least one unidimentionally measurable lesion by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and adequate system/organ function. Patients with significant cardiovascular disease, including a left ventricular ejection fraction (LVEF) less than 55%, completing radiation therapy or chemotherapy within 4 weeks, or having surgery within 2 weeks before treatment start were excluded. Written informed consent was received by all patients. Study protocol was approved by the Institutional Ethics Committees and was registered in [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), number NCT00484432.

Treatment plan
--------------

Primary objective of this multicentre, single-arm phase II trial was to assess the antitumour activity of the NGR-hTNF and doxorubicin combination in terms of objective response rate, defined as the proportion of patients with complete response (CR) or partial response (PR) according to the RECIST criteria. Radiological studies were done at baseline and every other cycle (6 weeks) by computed tomography or magnetic resonance imaging. Investigator-determined responses (CR or PR) had to be confirmed at least 4 weeks later. Disease control rate was defined as the percentage of patients who had a best-response rating of CR or PR, or stable disease (SD). Secondary efficacy variables included progression-free survival (PFS) and overall survival (OS). Here, PFS was defined on the basis of the first evidence of either radiological progression or death due to any cause, and OS was defined on the basis of the date of death due to any cause. For patients without documented progression or death at the time of analysis, PFS was censored at the last date of tumour evaluation and OS at the last date of follow-up. Additional secondary objectives included assessment of CA-125 response every other cycle, using the Gynaecological Cancer Intergroup (GCIG) criteria ([@bib21]), and evaluation of toxicity on an ongoing basis throughout the study using the Common Terminology Criteria for Adverse Events, version 3.0. Physical examinations and laboratory tests (complete blood counts and serum chemistries) were done at baseline and before each cycle (3 weeks).

The NGR-hTNF (0.8 *μ*g m^−2^) was given intravenously as 1-h infusion, followed by doxorubicin 60 mg m^−2^ as 15-min infusion, which was started 2 h after the beginning of the NGR-hTNF dosing. Maximum cumulative dose of doxorubicin was capped at 550 mg m^−2^, whereas NGR-hTNF was continued until progression, unacceptable toxicity, or patient request. For retreatment on next cycle, all toxicities should be recovered to grade 1 or less. For patients unable to meet retreatment criteria, a 1-to-3 week delay for both drugs was allowed. No formal dose reduction for NGR-hTNF was planned. Premedication with paracetamol was recommended for next cycles if chills had occurred on prior infusions. Doxorubicin dose was reduced by 25% for febrile neutropaenia or prolonged grade 4 neutropaenia, and by 50% in case of serum bilirubin levels between 1.2 to 3.0 mg dl^−1^. Doxorubicin was permanently discontinued in case of creatinine clearance \<60 ml min^−1^, grade ⩾3 neurotoxicity, New York Heart Association ⩾III congestive heart failure, and reduction of LVEF ⩾20% from baseline or to ⩽45% as absolute value.

Statistical analysis
--------------------

Primary study endpoint was response rate as per the RECIST criteria. Sample size was calculated using a Simon two-stage optimal design, with an expected response rate of 10% for a single-agent doxorubicin ([@bib16]; [@bib8]) and an increase up to 30% with the addition of NGR-hTNF. Accordingly, 17 patients were to be accrued in the first study stage. If at least 2 responses were registered, a total of 37 patients should be recruited, and study treatment could be considered worthy of further testing if 6 or more responses were documented. This two-stage design yielded a power of 90% to discriminate between true response rate of 10 and 30%. Type I alpha error was set at 5%. Maximal changes in tumour target lesions from baseline were also plotted as a waterfall plot, and changes over treatment in the sum of longest diameters of target lesions as a spider plot. Both PFS and OS were estimated by the Kaplan--Meier method with an intent-to-treat analysis. An exploratory, univariate Cox model was fit to examine the impact of baseline characteristics of outcome. Tested variables included age (as a continuous variable), ECOG PS (0 *vs* 1), PFI (lower than 6 months *vs* 6 to 12 months), and peripheral blood lymphocyte count (PBLC) at baseline (equal or higher *vs* lower than the 25th percentile distribution value). The log-rank test was used for comparisons of time-to-event data between subgroups of patients. Subset analyses were exploratory in nature. All analyses were performed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA) and GraphPad (GraphPad Software, Inc., San Diego, CA, USA).

Results
=======

Patient characteristics
-----------------------

A total of 37 patients with radiologically documented tumour progression after the last treatment regimen were enrolled. The median PFI was 4.6 months (95% CI 3.1--5.7). All patients had previously received both paclitaxel and a platinum compound. Baseline patient characteristics are listed in [Table 1](#tbl1){ref-type="table"}.

Toxicity
--------

Among all patients, 177 cycles (median 4, range 1--8) were delivered. Eighteen patients (49%) received at least 6 cycles and 12 patients (32%) received 8 courses. At the time of analysis, no patient was on treatment. Treatment discontinuations resulted from radiologic progression or symptomatic deterioration in 29 patients (78%), patient request in 7 cases (19%), and toxicity in 1 patient (3%).

Treatment-emergent adverse events (AEs), irrespective of relationship to study drugs, are displayed in [Table 2](#tbl2){ref-type="table"}. Non-haematologic grade 3 and 4 AEs were reported in 7 (19%) and 2 patients (5%), respectively. Two patients (5%) had grade 1 cardiac AEs (tachycardia and diastolic dysfunction). Only a small minority (50 out of 556, 9%) of all AEs recorded were related to NGR-hTNF infusion, being mostly represented by transient, infusion-related grade 1 or 2 chills in 24 patients (65%). Concerning the haematological toxicity, grade 3 and 4 neutropaenia were registered in 7 (19%) and 16 patients (43%), and grade 3 and 4 anaemia in 9 (24%) and 1 patient (3%), respectively. Only one patient (3%) had febrile neutropaenia. All cycles were given at the planned dose, with the exception of 8 patients (22%) who required dose reduction of doxorubicin.

Efficacy
--------

After enrolment of the first 17 patients, 6 PR were reported and the trial met its primary endpoint. After the second study stage (*n*=35 assessable patients), 8 PR (23% 95% CI 12--39) and 15 SD (43% 95% CI 28--59) were registered, for an overall disease control rate of 66% (95% CI 49--79). Among 23 patients assessable by the GCIG CA-125 criteria, there were 9 responses (39% 95% CI 22--59; 4 PR and 5 SD by the RECIST criteria). Median CA-125 levels at baseline and after 2, 4, 6, and 8 cycles were 556, 283, 124, 120, and 99 U ml^−1^, respectively. Efficacy results are summarised in [Table 3](#tbl3){ref-type="table"}, and individual patient radiological responses are plotted in [Figure 1](#fig1){ref-type="fig"}. Median PFS was 5.0 months for the whole study population ([Figure 2A](#fig2){ref-type="fig"}), 8.2 months (range 5.0--12.0) for patients who achieved PR, and 4.9 months (range 2.4--26.0) for patients who experienced SD.

After a median follow-up of 14.6 months, the estimated 1-year OS rate was 65% ([Figure 2B](#fig2){ref-type="fig"}). Median survival time was 24.0 months in patients with disease control and 4.9 months in patients with early progressive disease (*P*\<0.0001).

By univariate Cox analyses, both longer PFI (*P*=0.03) and higher baseline PBLC (*P*=0.01) were significantly associated with better PFS, whereas improved OS was noted in patients with a PS of 0 (*P*=0.002) and higher PBLC (*P*=0.001).

Kaplan--Meier curves of PFS and OS for the whole study population according to baseline PBLC are depicted in [Figure 3](#fig3){ref-type="fig"}. In the subset with refractory/resistant relapse, patients with PBLC higher or lower than 1.2 per ml (i.e., the 25th percentile distribution value) had a median PFS of 4.9 and 2.6 months (*P*=0.02), and median OS of 15.8 and 4.3 months (*P*=0.0001), respectively. Consistently, similar results were noted when these subset analyses were repeated by testing the neutrophil-to-lymphocyte ratio, with a cutoff value set at 4 (i.e., the 75th percentile distribution value; data not shown).

Discussion
==========

This phase II trial demonstrated that the combination of NGR-hTNF plus doxorubicin has interesting clinical activity and safe toxicity profile in relapsed ovarian cancer. A 23% response rate, with an overall disease control rate of 66% maintained for a median time of 6.6 months, a 5.0 months median PFS, and a 17.0 months median OS seem to be meaningful results, especially considering that two thirds of patients presented with platinum-refractory/resistant relapse. In particular, in this patient subset, disease control rate was 52%, median PFS was 3.8 months, and median OS was 14.3 months.

These results compare favourably with data recently reported by the Gynaecologic Oncology Group (GOG) in the same patient subset treated with single agents or combination regimens ([@bib20]). In this retrospective GOG analysis, disease control rate was 39%, median PFS was 2.4 months, and median OS was 10.2 months. Interestingly, the disease control rate correlated better with survival (*r*=0.75; *P*=0.008) compared with response rate (*r*=0.56; *P*=0.07).

Moreover, these results appear in line also with data from a recently published phase III trial (OVA-301 study; [@bib15]; [@bib18]) in recurrent ovarian cancer patients receiving the combination of PLD plus trabectedin, in terms of response rate (28%), median PFS (7.3 months), and median OS (22.4 months), considering that the proportion of patients with sensitive recurrences was higher in the OVA-301 trial (65%) than in the present study (32%).

Interestingly, in the present study, a strong association was observed between baseline lymphocyte counts and outcomes, especially in the refractory/resistant subset. It is increasingly recognised that patients with refractory/resistant relapse represent a heterogeneous group. In fact, when these patients were grouped on the basis of the baseline lymphocyte count lower or higher than the first quartile, significant differences were found in the PFS (median, 2.6 *vs* 4.9 months) and OS (median, 4.3 *vs* 15.8 months). Therefore, a low baseline lymphocyte count is associated with an early progression and a short survival, whereas a high lymphocyte count correlates with prolonged clinical benefit even in refractory/resistant disease. It is conceivable that patients with aggressive or chemotherapy-resistant disease may have an impaired antitumour immune response, as assessed by low lymphocyte counts. Accordingly, in the present study, the baseline lymphocyte counts tended to be lower in patients with refractory/resistant relapse than in patients with partially sensitive disease. These findings are consistent with a previously reported association between lack of intratumoural T lymphocytes and poor clinical outcome in advanced ovarian cancer ([@bib30]). Most importantly, these clinical observations are consistent with preclinical evidences of synergism between NGR-hTNF and doxorubicin shown in immunocompetent mice, being absent in nude mice lacking functional T cells ([@bib23]), and with the rapid increase of tumour-infiltrated lymphocytes noted in NGR-hTNF-treated mice ([@bib2]). In this view, the lymphocyte count could be an easily accessible and reproducible blood-based biomarker that might be exploited for selecting patients with refractory/resistant disease, who would mostly benefit from the combination of NGR-hTNF and doxorubicin. Given the exploratory nature of the analysis, however, these findings are only hypothesis-generating and should be confirmed by a larger size and controlled trial.

The toxicity profiles of the two drugs did not apparently overlap. Most commonly reported AEs were those typically expected when each agent is given alone, consisting of grade 3--4 neutropaenia (62% of patients) for doxorubicin and grade 1--2 chills (65% of patients) for NGR-hTNF. However, only one patient had febrile neutropaenia, whereas chills were short-lived and easily manageable. Notably, less than 10% of all recorded AEs were attributable to NGR-hTNF. Furthermore, the cardiovascular toxicities previously described for vascular targeting agents ([@bib27]) did not appear in the present study, and most importantly, despite half of patients completing six or more cycles of doxorubicin, there was no exacerbation of the well-known cardiotoxicity profile of doxorubicin. These findings confirm the tolerability of the combination previously reported in phase I ([@bib9]).

In conclusion, the evidence of a disease control achieved in more than half of patients and maintained for a median time of more than 6 months seem to be an interesting and remarkable result, especially in light of the manageable toxicity profile of the NGR-hTNF--doxorubicin combination. Given the outstanding use of PLD in ovarian cancer, and the preclinical synergism between low-dose TNF and liposomal formulation of doxorubicin ([@bib26]), a randomised phase II trial (NCT01358071) testing PLD with or without NGR-hTNF in recurrent, platinum-refractory/resistant ovarian cancer is currently open to accrual.
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![Individual patient radiological responses (*n*=31). (**A**) Maximal change from baseline of target lesions. (**B**) Change from baseline over treatment of the total sum of longest diameters of target lesions. Tumour measurements were not repeated in six patients because of development of new lesions (*n*=4) and clinical deterioration before reassessment (*n*=2). Each bar or full line represent an individual patient. Upper, intermediate, and lower dotted lines indicate progression, partial, or complete response, respectively, according to the RECIST criteria.](bjc2012233f1){#fig1}

![Kaplan--Meier estimates of (**A**) progression-free survival and (**B**) overall survival for the whole study population (*n*=37). Vertical ticks denote censored observations.](bjc2012233f2){#fig2}

![Kaplan--Meier estimates of (**A**) progression-free survival and (**B**) overall survival for the whole study population (*n*=37) according to the baseline peripheral blood lymphocyte count. Vertical ticks denote censored observations.](bjc2012233f3){#fig3}

###### Baseline patient characteristics

  **Characteristics**                           ***n=*37**   **%**
  --------------------------------------------- ------------ -------
  *ECOG PS*                                                  
   0                                            32           86
   1                                            5            14
                                                              
  *Number of prior systemic regimens*                        
   1                                            30           81
   2 or more                                    7            19
                                                              
  *PFI after last treatment*                                 
   \<6 months (refractory/resistant relapse)    25           68
   6--12 months (partially sensitive relapse)   12           32
                                                              
  *Patient age (years)*                                      
   Median                                       57           
   Range                                        35--72       
                                                              
  *CA-125 levels (U ml*^*−1*^)                               
   Median                                       556          
   Range                                        6--5687      
                                                              
  *Sum of longest tumour diameters (mm)*                     
   Median                                       90           
   Range                                        11--269      
                                                              
  *PBLC (per ml)*                                            
   Median                                       1.6          
   Interquartile range                          1.2--2.1     
                                                              
  *Neutrophil-to-lymphocyte ratio*                           
   Median                                       2            
   Interquartile range                          2--4         

Abbreviations: ECOG=Eastern Cooperative Oncology Group; PBLC=peripheral blood lymphocyte count; PFI=platinum-free interval; PS=performance status.

###### Adverse events (worst grade in more than 5% of patients) irrespective of relationship to study drugs (*n*=37)

                                         **Any grade**   **Grade 3**   **Grade 4**               
  -------------------------------------- --------------- ------------- ------------- ----- ----- -----
  Asthenia                               33              89            1             3      ---   ---
  Anaemia                                31              84            9             24      1     3
  Leukopaenia                            31              84            17            46      1     3
  Nausea                                 30              81            ---           ---    ---   ---
  Neutropaenia                           29              79            7             19     16    43
  Vomiting                               25              67            ---           ---    ---   ---
  Chills                                 24              65            ---           ---    ---   ---
  Constipation                           23              62            ---           ---    ---   ---
  Stomatitis                             19              51            1             3      ---   ---
  Paraesthesia                           15              41            ---           ---    ---   ---
  Headache                               8               22            ---           ---    ---   ---
  Platelet count increased               8               22            2             5      ---   ---
  Diarrhoea                              7               19            ---           ---    ---   ---
  Platelet count decreased               5               13            1             3      ---   ---
  Alanine aminotransferase increased     4               11            1             3      ---   ---
  Pyrexia                                4               11            ---           ---    ---   ---
  Gamma-glutamyltransferase increased    3               8             ---           ---     1     3
  Aspartate aminotransferase increased   3               8             1             3      ---   ---
  Dyspnoea                               3               8             1             3      ---   ---
  Herpes zoster infection                3               8             1             3      ---   ---
  Hypoalbuminaemia                       3               8             ---           ---    ---   ---
  Hypocalcaemia                          3               8             1             3      ---   ---
  Hyponatraemia                          3               8             2             5      ---   ---

###### Overall efficacy results

  **Best overall response, *n* (%)**       **All patients (*n*=35)**   **PFI\<6 months (*n*=23[a](#t3-fn1){ref-type="fn"})**   **PFI 6--12 months (*n*=12)**
  ---------------------------------------- --------------------------- ------------------------------------------------------- -------------------------------
  Partial response                         8 (23)                      2 (9)                                                   6 (50)
  Stable disease                           15 (43)                     10 (43)                                                 5 (42)
  Disease control rate                     23 (66)                     12 (52)                                                 11 (92)
  Progressive disease                      12 (34)                     11 (48)                                                 1 (8)
                                                                                                                                
  **Time-related endpoints, months**       **All patients (*n*=37)**   **PFI\<6 months (*n*=25)**                              **PFI 6--12 months (*n*=12)**
  *PFS*                                                                                                                        
   Median                                  5.0                         3.8                                                     7.8
   95% CI                                  3.1--6.9                    2.1--5.5                                                5.8--9.7
                                                                                                                                
  *PFS in patients with disease control*                                                                                       
   Median                                  6.6                         5.0                                                     7.8
   95% CI                                  4.4--8.7                    4.6--5.3                                                5.8--9.7
                                                                                                                                
  *OS*                                                                                                                         
   Median                                  17.0                        14.3                                                    20.1
   95% CI                                  10.4--23.6                  8.0--20.6                                               19.6--20.6

Abbreviations: CI=confidence interval; OS=overall survival; PFI=platinum-free interval; PFS=progression-free survival.

Two patients were withdrawn from study before their first radiological reassessment due to symptomatic deterioration.
